🚨BREAKING: Largest Real-World Study of Ivermectin Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Tumor Regression After just 6 months, 48.4% of cancer patients taking ivermectin and mebendazole reported NO EVIDENCE OF DISEASE (32.8%) or tumor regression (15.6%), while 36.1% reported disease stabilization⬇️ We have completed the largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology. The groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology. This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate). Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day. The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery. At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]): ✅ 32.8% reported no evidence of disease (95% CI: 25.1–41.5%) ✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%) ✅ 36.1% reported stable disease (95% CI: 28.1–44.9%) Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months. The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events. Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach. Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies. Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary. This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes. The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.” @twc_health @McCulloughFund @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson

Localised prostate cancer just changed. Again. ESMO 2026 brings clarity on who to observe, who to escalate, and which trials actually matter 👇 🧠 Diagnosis MRI before biopsy is standard High-resolution US is a valid alternative (RCT n=678) 🧭 Low risk Active surveillance is safe ProtecT 15-yr data shows similar survival vs RP/RT ☢️ Radiotherapy Shorter is better CHHiP ➜ moderate hypofractionation HYPO-RT-PC ➜ ultra-hypofractionation PACE-B ➜ SBRT works in selected IR disease 📈 High risk RT long-term ADT saves lives SPCG-7 | NCIC/MRC Dose escalation improves OS (GETUG-AFU 18) 🚨 Very high-risk / cN1 RT ADT abiraterone is the new benchmark STAMPEDE delivers MFS OS benefit 🔁 Biochemical recurrence Avoid routine adjuvant RT Early salvage RT preferred RADICALS-RT | RAVES | GETUG-AFU 17 High-risk BCR? Intensify EMBARK supports enzalutamide ADT 🧠 Bottom line Risk-adapted care > overtreatment Imaging-driven decisions Escalate only when trials prove benefit 📖 Full paper in comment ⬇️ #OncoTwitter #MedTwitter #ProstateCancer #GUOncology @OncoAlert @myesmo @esmo_open @asco @OncBrothers

People that don't know will just never know. It was one of the greatest atmospheres in all of college basketball. I was at the games yet I taped them on my VCR to watch again when I got home. There was literally nothing like being there. It's embarrassing now.

Small cell lung cancer (SCLC) is a smoking-related malignancy that presents at an advanced stage in 70% of patients. This narrative review summarizes the epidemiology, molecular characteristics, clinical presentation, and management of SCLC. ja.ma/4j5YgRF

There has been a dramatic transformation of care for pts w locally advanced #RectalCancer w overarching goal to better balance disease control w long-term #QoL & function. Experts discuss treatments, recent trial data: brnw.ch/21wO4pn @KrishanJethwa #GICSM #ASCODailyNews